Temafloxacin

Temafloxacin
Clinical data
Trade namesOmniflox
Routes of
administration		Oral
ATC code
Legal status
Legal status
  • Withdrawn
Identifiers
  • 1-(2,4-Difluorophenyl)-6-fluoro-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H18F3N3O3
Molar mass417.388 g·mol−1
3D model (JSmol)
  • Fc1ccc(c(F)c1)N\3c2cc(c(F)cc2C(=O)C(/C(=O)O)=C/3)N4CC(NCC4)C
  • InChI=1S/C21H18F3N3O3/c1-11-9-26(5-4-25-11)19-8-18-13(7-16(19)24)20(28)14(21(29)30)10-27(18)17-3-2-12(22)6-15(17)23/h2-3,6-8,10-11,25H,4-5,9H2,1H3,(H,29,30) checkY
  • Key:QKDHBVNJCZBTMR-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Temafloxacin (marketed by Abbott Laboratories as Omniflox) is a fluoroquinolone antibiotic drug which was withdrawn from sale in the United States shortly after its approval in 1992 because of serious adverse effects resulting in three deaths.[1][2] It is not marketed in Europe.

  1. ^ "Recalling the Omniflox (Temafloxacin) Tablets" (PDF). Food and Drug Administration. 1992-06-05. Retrieved 2014-10-15.
  2. ^ "ABBOTT WITHDRAWS TEMAFLOXACIN - Pharmaceutical industry news". The Pharmaletter. 1992-06-15. Retrieved 2014-10-16.